Parth

Radiation Oncologist.
Former Senior Clinical & Research fellow - Uro Oncology @RadOncTMC & @ACTREC_TMC
Alumnus @AmritaHospitals
Football | Coffee

[Parth @DrParthVermaa]

Account was suspiciously logged in on an unknown device.
Please do not respond to any fishy tweets/replies/DMs

[Shankar Siva @_ShankarSiva]

The primary is the source of first progression in >50% of cases of #lungcancer patients, and TRACERx showed us that in 32% of NSCLC the primary polyclonally seeds metastases. In our @IASLC consensus, now in JTO https://t.co/9LzfFi4ICc, makes the case for eradicating it with #radiotherapy. The EGFRm phase III data are the most compelling OS 34.4 vs 26.2 months with TKI+RT. There are still unresolved questions in the non-AGA population. We are opening the phase III PRIME-LUNG trial https://t.co/4J4JsgWu31 @TROGfightcancer @TOGAANZ to answer this question! #radonc

[Dr. Andrew Loblaw @DrAndrewLoblaw]

In comparison, what’s the relapse rate after radical Nephrectomy?

What say you Open Evidence…?

Maybe time for an RCT @_ShankarSiva ?

[Priyamvada Maitre @docpriyamvada]

🤩 Finally OUT in @JCO_ASCO!

BART RCT from 🇮🇳 largest ph3 for adjuvant RT in high risk MIBC post cystectomy

A decade of persistence from @VedangMurthy ☺️
@RadOncTMC @TataMemorial @ACTREC_TMC
@PaulSargos
@Xristodouleas

https://t.co/B8iTgImLHr

[Melissa Barber @MellyB_7]

@_ShankarSiva & @Forde_Elizabeth have a dream. And they have beautifully articulated how the Radiotherapy community can work together to make it a reality

[Vedang Murthy @VedangMurthy]

Is SBRT (36.25 Gy/5#) non-inferior to MHRT in high-risk & N+ prostate cancer?

526 patients, 3 centres, mpMRI + PSMA staging, 77% whole-pelvis RT.

Largest RCT in this population. From @TataMemorial @RadOncTMC 🔥
#ESTRO2026

[Vedang Murthy @VedangMurthy]

Very proud of my whole team esp @indranilsays for brilliantly presenting the 1y AE data of the largest RCT in HR and N+ CaP.
SBRT is safe! Gr 3 AE very low.
More to follow....

[Shankar Siva @_ShankarSiva]

#ESTRO26 - 📣 FASTRACKII final results, median F/U of 5 years. Thank you patients, funders, investigators - #kidneycancer #kcsm
1) 100% Local Control: No local recurrences were observed at 36, 60, or 84 months.
2) 100% Cancer-Specific Survival
3) Grade 3 AEs remain at 10%

[Jay Detsky @jaydetsky]

Claude's conclusion on the subject /end

[Shankar Siva @_ShankarSiva]

Really? Isn’t an editorial an opinion piece @DriesDeveltere? I hope you realise that if you used the same CTCAE scale for grading cumulative toxicity, you would have 100% G2+ indefinitely with prostatectomy…. Plenty of #radonc talk about these 2 trials cumulative AEs, which you would know if you had bothered to collaborate with one to write this editorial/opinion piece….

[James Janopaul-Naylor @jjnaylor02]

@DriesDeveltere @JCO_ASCO @RicBertolo While I agree it is easy to underestimate the burden of toxicity, I doubt cumulative incidence of Gr 2 is the best. A man who needs flomax for a month due to RT in my mind is similar to a man needing a catheter immediately after RP. Should we say RP causes 100% cumulative Gr 3?

[OncoAlert @OncoAlert]

Coverage of #APCCC26 🇨🇭 by @OncoAlert 🚨 Day Two
the indian perspective Presenter Dr. Vedang Murthy 🇮🇳

Same disease, different realities demand different decisions.
In resource-constrained settings, we adapt: act early, simplify care, prioritize logistics, and ensure feasibility. The goal is not just to chase optimal therapy, but focus on what is deliverable.
Solutions to inequality will come from generating local evidence, not importing guidelines.

@APCCC_Lugano
@Silke_Gillessen
@AOmlin
@weoncologists
@declangmurphy
@RenuEapen
@DrYukselUrun
@nataliagandur
@fabioturco92
@UrsulaVogl
@SScagliarini
@Tylersbrt
@neerajaiims
@amerseburger
@Cdanicas
@AarmstrongDuke
@BertrandTOMBAL
@ChrisSweens1
@EAntonarakis
@KOSJ12
@VedangMurthy
@DrRanaMcKay
@LoebStacy
@stefanofanti4
@mirrorsmed
@profkhermann
@dr_coops
@piet_ost
@_ShankarSiva
@DrSpratticus
@scocmem
@AmandaNizamMD
@tompowles1
@brian_rini
@Uromigos
@EUplatinum

#ProstateCancer #ProstateCancerWeek

[Parth @DrParthVermaa]

Highly recommended for anyone with a desire to be on the cutting edge of advancements in Uro Oncology.
#UroOncology

[Vedang Murthy @VedangMurthy]

Come and join us in the Uro Radiation Oncology Unit at @TataMemorial @RadOncTMC as a Fellow. Post MD/DNB.

You are guaranteed lots of fun! Get in touch if interested!

[Vedang Murthy @VedangMurthy]

Come and join us in the Uro Radiation Oncology Unit at @TataMemorial @RadOncTMC as a Fellow. Post MD/DNB.

You are guaranteed lots of fun! Get in touch if interested!

[Vedang Murthy @VedangMurthy]

Can PSA and PSMA kinetics together redefine how we assess response after prostate SBRT?

Ph2 PROBE Trial : PSMA-PET/MR–guided SBRT + DIL boost + 6m ADT
• 79% PSA <0.1 at 6 months
• PSMA response slower: CMR: 17% → 48% → 65% (end → 6m → 12m)
Read: https://t.co/xfDiwRAPmy

[Priyamvada Maitre @docpriyamvada]

Stereotactic Radiotherapy has transformed our field, and everyone should benefit!

🗺️From Constraints to Confidence: A Roadmap of 'Simple' SBRT 🗺️

Our thoughts in the SBRT special issue of @IJROBP 🥰
Free link⤵️
https://t.co/T2Mfc3pygm

[Dr. Nina Niu Sanford @NiuSanford]

Someone suggested I make a table summarizing the video. Here it is!

[Tata Memorial Centre @TataMemorialCtr]

85 years of care, compassion, and commitment.

Since 1941, @TataMemorial has remained dedicated to accessible cancer care, advancing research, and training the next generation of oncology professionals.

Honouring the legacy. Renewing the commitment.
#85YearsOfCare #FoundationDay

[The Lancet Oncology @TheLancetOncol]

🔴Online now: Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised #prostatecancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial

https://t.co/x5xngvO2qP

[Dr. Nina Niu Sanford @NiuSanford]

Hi everyone! Been a while, but back today with a teaching video on palliative RT for GI cancers.

IMO palliative RT can be v effective, but is underutilized.

Here is 13 min on indications, regimens, common q's re: palliative RT by GI site.

Slides & full video link below 🧵1/5.

[Dr Rishabh Jain @DrRishabhOnco]

Radical cystectomy is NOT the only standard for MIBC anymore. 🚻🔥

The International Bladder Cancer Group just made it crystal clear in European Urology 📘

If you remember ONE thing, remember this 👇

🧠 TMT = TURBT + RT + Chemo

That’s bladder preservation.
That’s guideline backed.
That’s no longer niche care.

Who wins with TMT 🎯
🟢 Single tumor
🟢 cT2
🟢 No hydronephrosis
🟢 No multifocal CIS
🟢 Good bladder function

Big myth busted ⚠️
cT3–4, CIS, hydronephrosis
👉 Worse prognosis ≠ absolute no

The safety net that makes this work 🛟
If local failure happens
👉 Early salvage cystectomy still cures

What is NOT routine 🚫
❌ Partial cystectomy for most
❌ Radical TUR alone
❌ Skipping local therapy after chemo or IO outside trials

One line takeaway 💡
If you never discuss TMT, you are denying patients a real option.

Would you offer TMT to every eligible MIBC patient ❓

📖 Full paper in comment ⬇️

#BladderCancer #UroOncology #OncoTwitter #MedTwitter #EAU

@OncoAlert @myESMO @ESMO_Open @Uromigos